HilleVax (HLVX) Stock Forecast, Price Target & Predictions
HLVX Stock Forecast
HilleVax stock forecast is as follows: an average price target of $32.00 (represents a 1620.43% upside from HLVX’s last price of $1.86) and a rating consensus of 'Hold', based on 3 wall street analysts offering a 1-year stock forecast.
HLVX Price Target
The average price target for HilleVax (HLVX) is $32.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $34.00 to $30.00. This represents a potential 1620.43% upside from HLVX's last price of $1.86.
HLVX Analyst Ratings
According to 3 Wall Street analysts, HilleVax's rating consensus is 'Hold'. The analyst rating breakdown for HLVX stock is 0 'Strong Buy' (0.00%), 1 'Buy' (33.33%), 2 'Hold' (66.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
HilleVax Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Mar 21, 2024 | Stephen Willey | Stifel Nicolaus | $34.00 | $15.87 | 114.24% | 1727.96% |
| May 25, 2022 | David Risinger | Leerink Partners | $30.00 | $10.11 | 196.74% | 1512.90% |
The latest HilleVax stock forecast, released on Mar 21, 2024 by Stephen Willey from Stifel Nicolaus, set a price target of $34.00, which represents a 114.24% increase from the stock price at the time of the forecast ($15.87), and a 1727.96% increase from HLVX last price ($1.86).
HilleVax Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $34.00 |
| Last Closing Price | $1.86 | $1.86 | $1.86 |
| Upside/Downside | -100.00% | -100.00% | 1727.96% |
In the current month, the average price target of HilleVax stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to HilleVax's last price of $1.86. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 09, 2024 | H.C. Wainwright | Neutral | Downgrade | |
| Jul 08, 2024 | Guggenheim | Buy | Neutral | Downgrade |
| May 25, 2022 | SVB Leerink | Outperform | Initialise | |
| May 24, 2022 | Guggenheim | Buy | Initialise |
HilleVax's last stock rating was published by H.C. Wainwright on Jul 09, 2024. The company Downgrade its HLVX rating from "null" to "Neutral".
HilleVax Financial Forecast
HilleVax Revenue Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Avg Forecast | - | - | - | - |
| High Forecast | - | - | - | - |
| Low Forecast | - | - | - | - |
| # Analysts | - | - | - | - |
| Surprise % | - | - | - | - |
HilleVax's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. HLVX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
HilleVax EBITDA Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| EBITDA | - | - | - | - |
| Avg Forecast | - | - | - | - |
| High Forecast | - | - | - | - |
| Low Forecast | - | - | - | - |
| Surprise % | - | - | - | - |
undefined analysts predict HLVX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than HilleVax's previous annual EBITDA (undefined) of $NaN.
HilleVax Net Income Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| Net Income | - | - | - | - |
| Avg Forecast | $-26.67M | $-18.64M | $-20.59M | $-38.43M |
| High Forecast | $-26.67M | $-15.21M | $-20.59M | $-38.43M |
| Low Forecast | $-26.67M | $-26.00M | $-20.59M | $-38.43M |
| Surprise % | - | - | - | - |
HilleVax's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. HLVX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
HilleVax SG&A Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| SG&A | - | - | - | - |
| Avg Forecast | - | - | - | - |
| High Forecast | - | - | - | - |
| Low Forecast | - | - | - | - |
| Surprise % | - | - | - | - |
HilleVax's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to HLVX last annual SG&A of $NaN (undefined).
HilleVax EPS Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| EPS | - | - | - | - |
| Avg Forecast | $-0.54 | $-0.38 | $-0.42 | $-0.78 |
| High Forecast | $-0.54 | $-0.31 | $-0.42 | $-0.78 |
| Low Forecast | $-0.54 | $-0.53 | $-0.42 | $-0.78 |
| Surprise % | - | - | - | - |
According to undefined Wall Street analysts, HilleVax's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to HLVX previous annual EPS of $NaN (undefined).
HilleVax Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HLVX | HilleVax | $1.90 | $32.00 | 1584.21% | Hold |
| STTK | Shattuck Labs | $1.15 | $12.00 | 943.48% | Hold |
| PEPG | PepGen | $4.30 | $29.50 | 586.05% | Buy |
| VIGL | Vigil Neuroscience | $1.73 | $11.00 | 535.84% | Buy |
| STRO | Sutro Biopharma | $2.09 | $13.00 | 522.01% | Buy |
| MOLN | Molecular Partners | $5.25 | $29.00 | 452.38% | Buy |
| CCCC | C4 Therapeutics | $4.05 | $20.00 | 393.83% | Buy |
| OPT | Opthea | $3.27 | $14.00 | 328.13% | Buy |
| IPSC | Century Therapeutics | $1.17 | $5.00 | 327.35% | Buy |
| PMVP | PMV Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
| CGEM | Cullinan Oncology | $11.49 | $34.00 | 195.91% | Buy |
| MLYS | Mineralys Therapeutics | $12.35 | $30.00 | 142.91% | Buy |
| PHVS | Pharvaris | $18.49 | $42.00 | 127.15% | Buy |
| EWTX | Edgewise Therapeutics | $30.17 | $46.25 | 53.30% | Buy |
| CNTA | Centessa Pharmaceuticals | $17.60 | $23.25 | 32.10% | Buy |
| TRDA | Entrada Therapeutics | $18.45 | $20.00 | 8.40% | Buy |